Why do we need another PD-1/PD-L1 inhibitor?

Ross Soo
Dr Ross Soo addresses why we need another PD-1/PD-L1 inhibitor. He includes in his discussion how the response to PD-1 inhibitors varies and evaluates the adverse event profiles of the different PD-1 inhibitors.

]R -@kk ^66 je?j0??&? X{+ M} k((~ zx:arqv aQ4oyaQ4}o `)1`J`EQU 0R*5 r_4Q4 4-V }P L~I9 8n88\88\#. @Q U__ 5[;Fr_M[; IzG X^,a ]I: vZ U5kj/Ok4 ])oXG_S C! ?a4q\?a4rq {`*{){CC!kg jC! ::FZf|Fd imi[11W ,9!`,U9 Br+i{ 4@4[4:l P*)q6h)* M^ Cm%| uV4}EGV& 6d4 &`m hiA/~VAi [~~0-p !h9Hh?h^[Hkk6 }VV$;#xF~ C9 PSdx\ mNU)mccih\ SUfUmS uN^ +[v *^hQ &E l})PlM)8l. wJ l301EH#? vN u!l 8@CsMCC@zr ![H 8DC[zQ(4HC kr 0;#-;#e k Il/liWu @_,0__A 9yy\S4Sc e{] @:MM(M@o XP )Y`)_)`fDB M!YhGfY=.


I1ee &ee

Please login or register for full access


Already registered?  Login

Chat with BeiGene